Blog
Latest articles from kanna.clinic
-
Access-and-benefit-sharing, explained (for kanna readers)
A plain-language intro to Nagoya Protocol ABS, South African biodiversity context, and why ‘wild-harvested kanna’ without paperwork is an ethical and quality red flag.
-
Fermented vs raw kanna: why the alkaloid profile differs
Traditional kougoed is fermented; many modern products are not. Here is what published chemistry implies about mesembrine-class shifts — without recipes or doses.
-
How to read a kanna extract label
A buyer-education checklist for Sceletium products: species, assay markers, solvents, fermentation, COAs, and disease-claim red flags — without brand rankings or doses.
-
Kanna and SSRIs: what we actually know (and don’t)
Why in vitro serotonin-reuptake activity raises interaction questions with SSRIs and other serotonergic drugs — and why controlled human combination data are still missing.
-
What the Zembrin cognition trial did and didn’t show
A plain-language reading of the Chiu et al. 2014 standardized Sceletium extract study: population, outcomes, limits, and why it is not an FDA approval or a dosing guide.
-
What Is Kanna? A Plain-English Guide for 2026
A clear, factual introduction to kanna (Sceletium tortuosum) — what it is, where it comes from, how it works, and what the current evidence base looks like.
-
Kanna vs Ketamine: How They Differ in Use, Legality, and Effects
A side-by-side comparison of kanna and ketamine — two very different substances that both attract interest in the mental wellness space, with distinct legal status and evidence bases.
-
Kanna's Regulatory Status in the US in 2026
Where kanna stands legally in the US in 2026 — not scheduled, sold as a supplement, but with real questions about labeling, marketing claims, and import compliance.